TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36250845

Group type: EXPERIMENTAL
Intervention: Potato extract for 49 days
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo for 49 days
Number of subjects: 184
Study: 33733479

Group type: EXPERIMENTAL
Intervention: 12-month exercise rehabilitation program (2 days/week, 60 minutes, personalized, one-on-one, resistance-based training)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 12-month exercise rehabilitation program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 80
Study: 32475836

Group type: EXPERIMENTAL
Intervention: Salud y Vida 2.0 (enhanced version)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Salud y Vida 1.0 (control program)
Number of subjects: 353
Study: 35915346

Group type: EXPERIMENTAL
Intervention: Conditioned open-label placebo (COLP)
Number of subjects: 18
Study: 33222405

Group type: EXPERIMENTAL
Intervention: Centrality measures (strength, betweenness, closeness) of mothers' baseline factors
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Strength at baseline
Number of subjects: 448
Study: 32069450

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 54

Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 54
Study: 34433114

Group type: EXPERIMENTAL
Intervention: Imagery‐Experiential elaboration condition (n=27)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Verbal‐Reasoning elaboration condition (n=28)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Scheduling‐only Control condition (n=26)
Number of subjects: 81
Study: 35220371

Group type: EXPERIMENTAL
Intervention: Endurance training (END)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Resistance training (RES)
Number of subjects: 72
Study: 32505495

Group type: EXPERIMENTAL
Intervention: IV ibuprofen (IVIB)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo or comparator medication
Number of subjects: 344
Study: 35542976

Group type: EXPERIMENTAL
Intervention: Clinical nomogram for predicting NAFLD
Number of subjects: 14251
Study: 35723855

Group type: COMPARATOR
Intervention: Moderate-intensity aerobic activity (MoIA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mild-intensity aerobic activity (MIA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 60
Study: 34652287

Group type: EXPERIMENTAL
Intervention: CAB+RPV long-acting Q2M
Number of subjects: 97

Group type: COMPARATOR
Intervention: dolutegravir/RPV
Number of subjects: 97
Study: 33607104

Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg/day from day 1-5, then 10 mg/day from day 6-10)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 34281901

Group type: EXPERIMENTAL
Intervention: Children with simple congenital ptosis
Number of subjects: 81

Group type: COMPARATOR
Intervention: Controls (age-matched and gender-matched)
Number of subjects: 81
Study: 33843971

Group type: EXPERIMENTAL
Intervention: Targeted interventions including site-based clinical leads, stakeholder meetings, a train-the-trainer workshop, targeted educational delivery, and audit and feedback.
Number of subjects: 3727

Group type: COMPARATOR
Intervention: Passive dissemination of an evidence-based bronchiolitis guideline (control group).
Number of subjects: 3727
Study: 36328879

Group type: EXPERIMENTAL
Intervention: CORBEVAX™ vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34554865

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 3104

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 3104

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3104
Study: 32462261

Group type: EXPERIMENTAL
Intervention: AC Paclitaxel (P)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: AC Docetaxel (D)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: PTX
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: DTX
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: CIA group
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: CIA
Number of subjects: 395
Study: 34212533

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study: 34337189

Group type: EXPERIMENTAL
Intervention: Tactile acuity training using the Imprint Tactile Acuity Device (iTAD) for four weeks.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo intervention using a de-activated TENS machine (iTENS) for four weeks.
Number of subjects: 36
Study: 34558338

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 2-week symptom reporting
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Experiencing susto
Number of subjects: 101
Study: 33631065

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg per kilogram of body weight)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Sarilumab (400 mg)
Number of subjects: 803

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Pooled interleukin‐6 receptor antagonists (tocilizumab and sarilumab)
Number of subjects: 803
Study: 32596348

Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinse (300 mg of caffeine in 25 mL of water)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose in 25 mL of water)
Number of subjects: 10
Study: 36081615

Group type: EXPERIMENTAL
Intervention: Home activity control system (Beprevent)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study: 33169543

Group type: EXPERIMENTAL
Intervention: e‐PTFE membrane (test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: d‐PTFE membrane (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both membranes (e‐PTFE and d‐PTFE)
Number of subjects: 12
Study: 34601588

Group type: EXPERIMENTAL
Intervention: Extended information about the CT examination including visualization of individual coronary calcium score images
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care (no extended information or examination result)
Number of subjects: 92
Study: 34445043

Group type: EXPERIMENTAL
Intervention: Urinary tartaric acid (biomarker of wine consumption)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Urinary tartaric acid
Number of subjects: 230
Study: 32123143

Group type: EXPERIMENTAL
Intervention: CTO percutaneous coronary intervention (PCI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No revascularization of the CTO
Number of subjects: 22
Study: 36306807

Group type: EXPERIMENTAL
Intervention: Methylphenidate plus educational intervention
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo plus behavioural parent training
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo plus educational intervention
Number of subjects: 153
Study: 32115035

Group type: EXPERIMENTAL
Intervention: Amino acid content in crop milk from day 1 (R1) to day 25 (R25) of chick rearing
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Amino acid content in plasma
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: mRNA abundances of AA transporters in male crops
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: mRNA abundances of AA transporters in female crops
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Gene expressions of enzymes involved in AA synthesis
Number of subjects: 84
Study: 36316911

Group type: EXPERIMENTAL
Intervention: 2-minute intermittent stretching (SS2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4-minute intermittent stretching (SS4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8-minute intermittent stretching (SS8)
Number of subjects: 30
Study: 33751155

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 32195960

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus Laser Acupuncture (LA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) plus sham Laser Acupuncture (LA) without laser output
Number of subjects: 50
Study: 35400624

Group type: EXPERIMENTAL
Intervention: Chamomile vaginal gel 5%
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen vaginal cream
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo vaginal gel
Number of subjects: 96
Study: 34226233

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) for soil-transmitted helminths, costing averaged US$1.14 per person per round in the first year of the trial, net of drugs.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothesised at-scale routine implementation scenario for cMDA, estimated US$0.11 per person treated per round.
Number of subjects: 0
Study: 35417763

Group type: EXPERIMENTAL
Intervention: Moderate hypofractionation (MHF) - 70 Gy in 28 daily fractions
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ultrahypofractionation (UHF) - 36.25 Gy in 5 weekly fractions
Number of subjects: 78
Study: 33554587

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Medium-dose vitamin D3 supplementation
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Low-dose vitamin D3 supplementation
Number of subjects: 450
Study: 32135010

Group type: EXPERIMENTAL
Intervention: LDL cholesterol genetic score (1760 variants)
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Main-effect genetic risk score for LDL cholesterol
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Downstream disease outcomes
Number of subjects: 9000
Study: 34376277

Group type: EXPERIMENTAL
Intervention: Mild anemia group (Hb 10≤ Hb <13 g/dl for men and 10≤ Hb <12 g/dl for women)
Number of subjects: 1677

Group type: COMPARATOR
Intervention: Non-anemia group (Hb ≥13 g/dl for men and Hb ≥12 g/dl for women)
Number of subjects: 1677
Study: 32669371

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) combined with pembrolizumab
Number of subjects: 36

Group type: COMPARATOR
Intervention: Talimogene laherparepvec (T-VEC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pembrolizumab
Number of subjects: 36
Study: 36189549

Group type: EXPERIMENTAL
Intervention: 0.2% Glyceryl Trinitrate (GTN) ointment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lateral Internal Sphincterotomy (LIS)
Number of subjects: 94
Study: 34157116

Group type: EXPERIMENTAL
Intervention: DHEAS (measured in μmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHEAS
Number of subjects: 0
Study: 34589887

Group type: EXPERIMENTAL
Intervention: Active transcutaneous cervical VNS (tcVNS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tcVNS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active tcVNS
Number of subjects: 30
Study: 36233711

Group type: EXPERIMENTAL
Intervention: Women with AF and CAD
Number of subjects: 461

Group type: COMPARATOR
Intervention: Men with AF and CAD
Number of subjects: 461

Group type: COMPARATOR
Intervention: Both genders
Number of subjects: 461
Study: 33980157

Group type: EXPERIMENTAL
Intervention: Polypharmacy (use of five or more medications)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Younger age group (18‐29 years)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Non-consumption of whole grains
Number of subjects: 150
Study: 36345818

Group type: EXPERIMENTAL
Intervention: DBBM‐C with porcine collagen matrix (CM)
Number of subjects: 42
Study: 33451904

Group type: EXPERIMENTAL
Intervention: 1.5T MRI
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 3.0T MRI
Number of subjects: 160

Group type: COMPARATOR
Intervention: Static Ultrasound (US)
Number of subjects: 160

Group type: COMPARATOR
Intervention: All modalities (1.5T MRI, 3.0T MRI, Static US)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 160
Study: 35206179

Group type: EXPERIMENTAL
Intervention: H2 inhalation, 2 × 60 min/day for 14 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 50
Study: 34067980

Group type: EXPERIMENTAL
Intervention: Microcurrent stimulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: False microcurrent stimulation (Control)
Number of subjects: 28
Study: 32327254

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab therapy
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: PRN ranibizumab therapy
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Loading dose treatment
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Fluid/function correlation
Number of subjects: 1095
Study: 35144024

Group type: EXPERIMENTAL
Intervention: Mailed fecal immunochemical test (FIT) kits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colonoscopy invitations
Number of subjects: 0
Study: 34000236

Group type: EXPERIMENTAL
Intervention: Cytokine adsorption using the CytoSorb device
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no cytokine adsorption)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cytokine adsorption
Number of subjects: 34
Study: 32481240

Group type: EXPERIMENTAL
Intervention: Halliwick (Hallw)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aquatic Plyometric Exercise (APE)
Number of subjects: 30
Study: 35463130

Group type: EXPERIMENTAL
Intervention: nVNS therapy plus standard of care (SoC), 2 consecutive 2-min doses of nVNS 3 times daily as prophylaxis.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: nVNS therapy plus standard of care (SoC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: standard of care (SoC) alone
Number of subjects: 110
Study: 33949703

Group type: EXPERIMENTAL
Intervention: Interactive sexual and reproductive health education program (two 40-min sessions)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Usual mode of sexual and reproductive health education
Number of subjects: 469
Study: 33009629

Group type: EXPERIMENTAL
Intervention: Etifoxine 150 mg/day for 12 weeks
Number of subjects: 179

Group type: COMPARATOR
Intervention: Clonazepam 1 mg/day for 12 weeks
Number of subjects: 179
Study: 35120656

Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy with ustekinumab (6 mg/kg IV at baseline, 90 mg SC at week 8, and potential escalation to every 4 weeks based on SES-CD improvement)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy with ustekinumab
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard-of-care strategy with ustekinumab (6 mg/kg IV at baseline, 90 mg SC at week 8, and potential escalation per European labelling)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard-of-care strategy with ustekinumab
Number of subjects: 440
Study: 33246270

Group type: EXPERIMENTAL
Intervention: Integrated nomogram
Number of subjects: 124

Group type: COMPARATOR
Intervention: Clinical nomogram
Number of subjects: 124

Group type: COMPARATOR
Intervention: Radiomics nomogram
Number of subjects: 124
Study: 32669099

Group type: COMPARATOR
Intervention: Normal saline (100 ml twice daily starting from 3 days before the operation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA 1.5 g twice daily starting from 3 days before the operation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TXA 1.5 g administered 30 min before the operation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Normal saline and TXA)
Number of subjects: 0
Study: 36414207

Group type: EXPERIMENTAL
Intervention: Digital health intervention (DHI) including digital monitoring of sleep, meals, and physical activity plus weekly motivational health coaching
Number of subjects: 200

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) consisting of weekly telephone calls and similar assessment schedules
Number of subjects: 200
Study: 33723110

Group type: EXPERIMENTAL
Intervention: Hospital-based pulmonary rehabilitation (PR) program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Self-management pulmonary rehabilitation (PR) program
Number of subjects: 58
Study: 32635494

Group type: EXPERIMENTAL
Intervention: Oceanix (OCX) 25 mg for 14 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Exercise + OCX 2 (5.1 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Exercise + OCX 1 (2.55 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no exercise and placebo)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Exercise (E)
Number of subjects: 14
Study: 35690859

Group type: EXPERIMENTAL
Intervention: Machine learning model using plasma cfDNA fragmentomics
Number of subjects: 1214
Study: 34186531

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ketamine (6 intravenous infusions over 3 weeks)
Number of subjects: 28
Study: 35730553

Group type: EXPERIMENTAL
Intervention: Bright light (1300 lux) during wakefulness
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dim light (6 lux) during wakefulness
Number of subjects: 8
Study: 33791829

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg plus FDCSL (400/90 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: FDCSL (400/90 mg) alone
Number of subjects: 12
Study: 32910912

Group type: EXPERIMENTAL
Intervention: Deltamethrin-impregnated collars for dogs
Number of subjects: 6922

Group type: EXPERIMENTAL
Intervention: Praziquantel for dog deworming
Number of subjects: 6922

Group type: EXPERIMENTAL
Intervention: Health education campaigns
Number of subjects: 6922

Group type: EXPERIMENTAL
Intervention: Canine rabies vaccination
Number of subjects: 6922
Study: 35674708

Group type: COMPARATOR
Intervention: Mobile information communication technology devices and applications
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Telehealth program for promoting patient self‐management
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Structured rehabilitation with mobile self‐monitoring
Number of subjects: 16
Study: 34185550

Group type: EXPERIMENTAL
Intervention: Meditation-Based Lifestyle Modification (MBLM)
Number of subjects: 12
Study: 32810088

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (30 units in 1000ml normal saline at 15 units/hour during surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 60
Study: 34412546

Group type: EXPERIMENTAL
Intervention: Patient-centered communication style (PC group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Doctor-centered communication style (DC group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No consultation (control group)
Number of subjects: 120
Study: 32791086

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Mycophenolate mofetil plus dexamethasone
Number of subjects: 138
Study: 33959169

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 U weekly for 6 weeks followed by 1000 U daily for deficiency; 1000 U daily for insufficiency)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 132
Study: 35918547

Group type: EXPERIMENTAL
Intervention: Haptic simulator training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-haptic simulator training
Number of subjects: 36
Study: 33607244

Group type: EXPERIMENTAL
Intervention: Mediation analyses of health interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Published mediation analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
Number of subjects: 0
Study: 35484491

Group type: EXPERIMENTAL
Intervention: Electronic recruitment strategies (email communication, synchronous video presentations)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Email communication from clinic leaders
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Synchronous video presentations
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Recruitment costs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Challenges faced
Number of subjects: 45
Study: 34847908

Group type: EXPERIMENTAL
Intervention: IMARA‐SA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Health promotion control program
Number of subjects: 60
Study: 34128999

Group type: EXPERIMENTAL
Intervention: Eptinezumab, 100 mg
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 32825817

Group type: EXPERIMENTAL
Intervention: Goal-directed lactated Ringer's solution (crystalloid)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydroxyethyl starch 6% 130/0.4 (colloid)
Number of subjects: 120
Study: 34608092

Group type: EXPERIMENTAL
Intervention: Resilient Hyaluronic Acid Redensity (RHAR) filler
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study: 33030563

Group type: EXPERIMENTAL
Intervention: MK-7 (375 μg daily)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 33051943

Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 0
Study: 34581941

Group type: EXPERIMENTAL
Intervention: Auriculotherapy
Number of subjects: 166

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 166
Study: 32947017

Group type: EXPERIMENTAL
Intervention: Palliative Care (PC) cohort
Number of subjects: 2983

Group type: COMPARATOR
Intervention: Regional comparison cohort
Number of subjects: 2983

Group type: COMPARATOR
Intervention: Two-state comparison cohort
Number of subjects: 2983

Group type: COMPARATOR
Intervention: Eight-state comparison cohort
Number of subjects: 2983
Study: 33536005

Group type: EXPERIMENTAL
Intervention: AGLR > 90
Number of subjects: 495

Group type: COMPARATOR
Intervention: AGLR ≤ 90
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: AGLR
Number of subjects: 495
Study: 36367386

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (placebo)
Number of subjects: 27
Study: 34115035

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 119